![Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS - Annals of Oncology Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/43ca7cd4-144b-4115-94a6-5ef72c239b0e/gr1_lrg.jpg)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS - Annals of Oncology
![Immersive Virtual Environments and Wearable Haptic Devices in rehabilitation of children with neuromotor impairments: a single-blind randomized controlled crossover pilot study | Journal of NeuroEngineering and Rehabilitation | Full Text Immersive Virtual Environments and Wearable Haptic Devices in rehabilitation of children with neuromotor impairments: a single-blind randomized controlled crossover pilot study | Journal of NeuroEngineering and Rehabilitation | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12984-020-00771-6/MediaObjects/12984_2020_771_Fig4_HTML.png)
Immersive Virtual Environments and Wearable Haptic Devices in rehabilitation of children with neuromotor impairments: a single-blind randomized controlled crossover pilot study | Journal of NeuroEngineering and Rehabilitation | Full Text
![Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) - The Lancet Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d314687b-81bc-4d52-9ffc-6be0db0ff818/gr1.jpg)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) - The Lancet
![The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck - International Journal of Radiation Oncology, Biology, Physics The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck - International Journal of Radiation Oncology, Biology, Physics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/92bdc805-aa8f-4050-8080-ca1f29daef5d/gr1.jpg)
The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck - International Journal of Radiation Oncology, Biology, Physics
![MR-guided Focused Ultrasound Facilitates Sonodynamic Therapy with 5-Aminolevulinic Acid in a Rat Glioma Model | Scientific Reports MR-guided Focused Ultrasound Facilitates Sonodynamic Therapy with 5-Aminolevulinic Acid in a Rat Glioma Model | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-46832-2/MediaObjects/41598_2019_46832_Fig1_HTML.png)
MR-guided Focused Ultrasound Facilitates Sonodynamic Therapy with 5-Aminolevulinic Acid in a Rat Glioma Model | Scientific Reports
![Frontiers | Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts | Allergy Frontiers | Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts | Allergy](https://www.frontiersin.org/files/Articles/741788/falgy-02-741788-HTML/image_m/falgy-02-741788-t001.jpg)
Frontiers | Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts | Allergy
![Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2018/jco.2018.36.issue-17/jco.2017.77.6385/20180524/images/large/jco.2017.77.6385t6.jpeg)